[Standard and high doses of XXXX . Clinical, pharmacokinetic and pharmacodynamic aspects].

@entity1 @entity716 @entity1767 @entity935
The investigation was designed to study plasma drug concentration and prolactin response determined by two different doses of @entity1767 , a standard one and four-fold higher the other, and to explore the relationships between clinical effects and pharmacokinetic and physiological variables in @entity716 @entity1 . 24 @entity716 @entity1 received @entity1767 during 40 consecutive days. During the first 10 days they received 0,25 mg/kg b.w. During the next 20 days they were given 1 mg/kg b.w. Finally they received 0,25 mg/kg b.w. during the last ten days. The @entity1 were clinically assessed and plasma @entity1767 and prolactin concentrations were determined on days 0, 5, 10, 20, 30 and 40. In the range of dose studied, the use of higher than conventional doses of @entity1767 results in an increased concentration in the cellular site of action and in a more complete blockade of central @entity935 receptors. Prolactin response was positive correlated with serum @entity1767 concentration. Clinical remission was not direct correlated, neither with serum neuroleptic concentration nor with prolactin level. Those @entity1 who reached higher levels of plasmatic neuroleptic and prolactin concentrations were more susceptible to develop severe extrapyramidal side-effects. Pharmacokinetic and pharmacodynamic monitoring of neuroleptic treatment could be useful to identify these @entity1 .
